Published in Antiviral Res on February 04, 2008
Development of Immune Globulin Treatment for Avian Flu | NCT00383071
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults | NCT00921726
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol (2012) 1.90
Animal models for the study of influenza pathogenesis and therapy. Antiviral Res (2009) 1.90
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One (2010) 1.86
Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res (2008) 1.47
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One (2013) 1.19
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res (2009) 1.16
An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol (2010) 1.12
Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol (2012) 1.06
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release (2010) 1.05
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother (2009) 1.04
Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding. Biophys J (2012) 1.02
A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One (2011) 0.97
MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One (2012) 0.96
A(H5N1) Virus Evolution in South East Asia. Viruses (2009) 0.96
Antiviral strategies for pandemic and seasonal influenza. Viruses (2010) 0.95
The tree shrew provides a useful alternative model for the study of influenza H1N1 virus. Virol J (2013) 0.94
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs. PLoS One (2013) 0.91
A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine (2011) 0.91
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) (2013) 0.89
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother (2012) 0.86
Lactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunity. PLoS One (2013) 0.85
New prospects for the rational design of antivirals. Nat Med (2009) 0.84
Secondary structure of a conserved domain in an intron of influenza A M1 mRNA. Biochemistry (2014) 0.82
Evidence for a novel gene associated with human influenza A viruses. Virol J (2009) 0.81
Successful management of fulminant influenza A subtype H1N1 myocarditis. BMJ Case Rep (2010) 0.81
Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly. Exp Gerontol (2014) 0.81
Molecular imaging of influenza and other emerging respiratory viral infections. J Infect Dis (2011) 0.80
Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Biochemistry (2015) 0.79
A proline-based neuraminidase inhibitor: DFT studies on the zwitterion conformation, stability and formation. Int J Mol Sci (2009) 0.79
Monoclonal antibodies targeting the synthetic peptide corresponding to the polybasic cleavage site on H5N1 influenza hemagglutinin. J Biomed Sci (2012) 0.79
The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model. PLoS One (2015) 0.79
Characterization and pharmacological potential of Lactobacillus sakei 1I1 isolated from fresh water fish Zacco koreanus. Daru (2016) 0.78
Computational studies on the substrate interactions of influenza A virus PB2 subunit. PLoS One (2012) 0.78
Replication-competent fluorescent-expressing influenza B virus. Virus Res (2015) 0.78
A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease. PLoS One (2011) 0.78
Mutations Designed by Ensemble Defect to Misfold Conserved RNA Structures of Influenza A Segments 7 and 8 Affect Splicing and Attenuate Viral Replication in Cell Culture. PLoS One (2016) 0.76
Inhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian Drugs. Front Microbiol (2016) 0.76
Pandemism of swine flu and its prospective drug therapy. Eur J Clin Microbiol Infect Dis (2012) 0.76
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A (2016) 0.76
Investigating the role of MRGPRC11 and capsaicin-sensitive afferent nerves in the anti-influenza effects exerted by SLIGRL-amide in murine airways. Respir Res (2016) 0.75
Replication-Competent Influenza A Viruses Expressing Reporter Genes. Viruses (2016) 0.75
Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors. Int J Mol Sci (2010) 0.75
Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis (2016) 0.75
Inhibition of endosomal fusion activity of influenza virus by Rheum tanguticum (da-huang). Sci Rep (2016) 0.75
Complexes of Oligoribonucleotides with D-Mannitol Inhibit Hemagglutinin-Glycan Interaction and Suppress Influenza A Virus H1N1 (A/FM/1/47) Infectivity In Vitro. Pharmaceuticals (Basel) (2017) 0.75
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med (2006) 14.21
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet (1998) 12.89
Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A (2004) 12.39
Avian flu: influenza virus receptors in the human airway. Nature (2006) 11.28
Human infection with influenza H9N2. Lancet (1999) 9.73
Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med (2002) 9.47
Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet (2002) 8.70
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Neuraminidase inhibitors for influenza. N Engl J Med (2005) 7.79
Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med (2006) 7.74
Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet (2004) 7.52
Antivirals for influenza in healthy adults: systematic review. Lancet (2006) 7.20
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med (2005) 6.47
H5N1 Virus Attachment to Lower Respiratory Tract. Science (2006) 6.34
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature (2006) 6.00
The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med (2006) 5.94
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis (2007) 5.39
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med (2006) 5.28
Replication of avian influenza viruses in humans. Arch Virol (1991) 5.10
Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol (2002) 5.09
Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol (2005) 5.04
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 4.99
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med (2003) 4.86
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
Preparing for the next pandemic. N Engl J Med (2005) 4.65
Oseltamivir resistance--disabling our influenza defenses. N Engl J Med (2005) 4.41
Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res (2005) 4.41
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol (2001) 4.08
Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol (2006) 4.00
Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med (2007) 3.75
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol (2006) 3.60
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med (2007) 3.57
Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis (2002) 3.45
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol (2004) 3.43
Influenza A H5N1 replication sites in humans. Emerg Infect Dis (2005) 3.21
In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother (2002) 3.17
Antiviral agents active against influenza A viruses. Nat Rev Drug Discov (2006) 3.12
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res (2002) 3.07
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res (2002) 3.04
Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J Virol (2000) 2.84
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol (2007) 2.77
Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis (2006) 2.76
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem (2000) 2.74
Identification of H2N3 influenza A viruses from swine in the United States. Proc Natl Acad Sci U S A (2007) 2.73
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis (2005) 2.72
Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol (1995) 2.70
Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A (2007) 2.63
Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med (2007) 2.53
Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis (2006) 2.52
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother (2001) 2.46
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother (2005) 2.32
In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother (2007) 2.21
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother (2001) 2.21
Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A (2004) 2.21
Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res (2006) 2.15
Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res (2006) 2.11
Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09
Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother (2007) 2.03
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother (2006) 2.00
Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol (2007) 1.97
Antiviral resistance in influenza viruses--implications for management and pandemic response. N Engl J Med (2006) 1.95
Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A (2004) 1.91
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis (2007) 1.85
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol (2006) 1.74
Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol (2007) 1.73
Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol (1994) 1.72
The critically ill avian influenza A (H5N1) patient. Crit Care Med (2007) 1.65
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother (2003) 1.63
Atypical avian influenza (H5N1). Emerg Infect Dis (2004) 1.60
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther (2007) 1.52
Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother (2006) 1.51
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother (1999) 1.49
Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res (2007) 1.49
Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res (2006) 1.44
Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res (2005) 1.42
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
Influenza virus infection of desialylated cells. Glycobiology (2000) 1.35
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1--a review. Hum Pathol (2006) 1.30
In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res (2005) 1.25
Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ (2007) 1.22
Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother (2003) 1.21
Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis (1980) 1.21
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol (2007) 1.18
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther (2003) 1.18
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med (2010) 3.91
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis (2011) 2.52
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res (2003) 2.31
Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis (2004) 2.25
Ebola hemorrhagic fever and septic shock. J Infect Dis (2003) 2.19
Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res (2013) 1.93
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog (2009) 1.78
Imaging findings in a fatal case of pandemic swine-origin influenza A (H1N1). AJR Am J Roentgenol (2009) 1.63
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother (2002) 1.49
Subunit recombinant vaccine protects against monkeypox. J Immunol (2006) 1.44
Computer-assisted detection of infectious lung diseases: a review. Comput Med Imaging Graph (2011) 1.43
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology (2003) 1.40
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis (2007) 1.37
Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine (2003) 1.29
Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res (2003) 1.29
Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol (2002) 1.28
Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis (2007) 1.20
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis (2011) 1.12
Filovirus infection of STAT-1 knockout mice. J Infect Dis (2011) 1.10
Mouse models for filovirus infections. Viruses (2012) 1.07
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J (2010) 1.02
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res (2004) 0.95
Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg Infect Dis (2007) 0.93
Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J Virol (2009) 0.93
Eczema vaccinatum. Clin Infect Dis (2012) 0.90
Progress in the experimental therapy of severe arenaviral infections. Future Microbiol (2011) 0.90
Andes virus infection of cynomolgus macaques. J Infect Dis (2002) 0.89
Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob Agents Chemother (2003) 0.87
The role of radiology in influenza: novel H1N1 and lessons learned from the 1918 pandemic. J Am Coll Radiol (2010) 0.85
Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents. Biosecur Bioterror (2009) 0.80
Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. Arch Virol (2011) 0.79
Henry Kempe and the birth of vaccinia immune globulin. Clin Infect Dis (2004) 0.78
New data in a 200-year investigation. Clin Infect Dis (2003) 0.78
Keeping an eye on poxviruses. Am J Trop Med Hyg (2009) 0.78
Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways. J Interferon Cytokine Res (2013) 0.78
Potential applications of conventional and molecular imaging to biodefense research. Clin Infect Dis (2005) 0.77
Understanding smallpox vaccination. J Infect Dis (2011) 0.75